Monopar rises on drug licensing deal with AstraZeneca

Monopar Therapeutics

24/10/2024 16:53

(Updates)
    ** Drug developer Monopar Therapeutics'  MNPR.O  shares up
more than four-fold at $19.38, its highest in more than a year
    ** Company signs agreement with AstraZeneca  AZN.L  unit
Alexion for the license to AZN's experimental drug being tested
for Wilson disease, a rare genetic condition that causes the
buildup of toxic copper levels
    ** Monopar will be responsible for future global development
and drug commercialization activities
    ** Under deal terms, Monopar will pay Alexion an upfront in
cash and equity in Monopar
    ** As of last close, Monopar stock has more than tripled YTD

 (Reporting by Sruthi Narasimha Chari and Christy Santhosh in
Bengaluru)
 ((Sruthinarasimha.chari@thosmonreuters.com))